Thuau François, Kanlagna Anoujat, Verdier Julien, Perrot Pierre, Lancien Ugo
Plastic, Reconstructive, and Aesthetic Surgery Unit, Nantes University Hospital, Nantes, France.
Laboratory Regenerative Medicine and Skeleton (RMeS), INSERM, UMRS 1229, Nantes, France.
Int J Transgend Health. 2024 Feb 5;26(3):743-749. doi: 10.1080/26895269.2024.2311757. eCollection 2025.
Chest masculinization is currently the most commonly performed gender-affirming surgery. It is often preceded by testosterone replacement therapy, whose duration is not agreed upon before surgery. Our study evaluates the postoperative satisfaction of transgender men who have undergone chest masculinization surgery according to their preoperative hormonal treatment duration.
We conducted a single-center prospective study conducted from 2021 to 2022. All transgender men older than 18 years who had chest masculinization surgery were included. Demographic data, medical history, operative data, and duration of preoperative hormone therapy were collected. Participants completed the BREAST-Q© and BODY-Q© questionnaires pre- and postoperatively.
Forty-six patients were included, with a median age of 21 years (18-45 years). The median preoperative testosterone duration was 596 days (186-4479 days). A significant improvement was found in BREAST-Q© (psychosocial, sexual and physical well-being; satisfaction with chest) and BODY-Q© (satisfaction with chest and nipples) parameters ( < 0.01). There was no significant correlation between preoperative hormone therapy time and chest satisfaction of BREAST-Q© ( = 0.069; R2 = 0.002; = 0.647) and BODY-Q© (ρ = -0.114; R2 = 0.007; = 0.450).
All patients in our study were exposed to exogenous testosterone for at least six months. Our study suggests that satisfaction remains unchanged with a longer duration of usage, indicating that an extended period of hormone impregnation may not be necessary before performing chest masculinization surgery in transgender men. Furthermore, the findings confirm a significantly high post-operative satisfaction rate among participants, emphasizing the positive impact of this type of surgery.
胸部男性化手术目前是最常进行的性别确认手术。术前通常会进行睾酮替代疗法，但其疗程在手术前并无定论。我们的研究根据术前激素治疗疗程评估接受胸部男性化手术的跨性别男性术后的满意度。
我们于2021年至2022年开展了一项单中心前瞻性研究。纳入所有年龄超过18岁且接受过胸部男性化手术的跨性别男性。收集人口统计学数据、病史、手术数据以及术前激素治疗疗程。参与者在术前和术后完成BREAST-Q©和BODY-Q©问卷。
纳入46例患者，中位年龄21岁（18 - 45岁）。术前睾酮治疗的中位疗程为596天（186 - 4479天）。BREAST-Q©（心理社会、性和身体健康；对胸部的满意度）和BODY-Q©（对胸部和乳头的满意度）参数有显著改善（<0.01）。术前激素治疗时间与BREAST-Q©（=0.069；R2 = 0.002；=0.647）和BODY-Q©（ρ = -0.114；R2 = 0.007；=0.450）的胸部满意度之间无显著相关性。
我们研究中的所有患者都接受了至少六个月的外源性睾酮治疗。我们的研究表明，使用时间延长，满意度仍保持不变，这表明在跨性别男性进行胸部男性化手术前，可能无需延长激素预处理时间。此外，研究结果证实参与者术后满意度显著较高，强调了这类手术的积极影响。
